Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolododekin Alfa (ANK-101) + Anti-PD-1/PD-L1 in Advanced NSCLC
NCT07027514Phase 1Recruiting
- Sponsor
- Ankyra Therapeutics
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolododekin alfa in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Ankyra Therapeutics. Primary endpoint: Objective Response Rate at 6 months. Started Oct 2025; status: recruiting.
02
Drugs
tolododekin alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07027514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027514.